chronic
obstruct
pulmonari
diseas
copd
airway
lung
diseas
impair
immun
lung
defens
system
make
suscept
bacteri
copd
patient
may
experi
acut
exacerb
due
bacteri
global
initi
chronic
obstruct
lung
diseas
gold
guidelin
recommend
use
antibiot
bacteri
infect
suspect
event
acut
exacerb
chronic
obstruct
pulmonari
diseas
aecopd
gold
guidelin
also
suggest
symptom
increas
dyspnea
sputum
volum
sputum
purul
criteria
antibiot
sinc
symptom
present
absolut
numer
valu
use
antibiot
base
clinic
experi
judgment
henc
antibiot
often
overus
stray
gold
guidelin
report
studi
conduct
solv
problem
variou
biomark
distinguish
bacteri
infect
studi
includ
creactiv
protein
crp
procalcitonin
howev
crp
commonli
elev
viral
infect
henc
specif
distinguish
bacteri
procalcitonin
use
distinguish
bacteri
infect
expens
less
therefor
need
biomark
specif
distinguish
bacteri
infect
costeffect
userfriendli
known
eosinophil
lower
pneumonia
infecti
diseas
caus
eosinophil
simpl
test
easili
measur
inexpens
use
clinic
field
thu
purpos
studi
determin
whether
eosinophil
could
use
determin
bacteri
infect
aecopd
event
retrospect
review
analyz
medic
record
aecopd
event
patient
admit
korea
univers
guro
hospit
januari
may
search
electron
medic
record
databas
use
keyword
copd
acut
exacerb
studi
approv
institut
review
board
studi
retrospect
studi
patient
consent
necessari
maintain
patient
confidenti
declar
helsinki
copd
diagnos
base
gold
guidelin
ratio
forc
expiratori
volum
first
second
forc
vital
capac
less
postbronchodil
spirometri
prior
admiss
aecopd
defin
acut
event
character
worsen
patient
respiratori
symptom
beyond
normal
daytoday
variat
lead
chang
medic
patient
older
year
patient
exclud
caus
admiss
aecopd
exampl
acut
heart
failur
acut
pulmonari
edema
acut
pulmonari
embol
pneumothorax
arrhythmia
comorbid
could
affect
eosinophil
count
exampl
cancer
allerg
disord
autoimmun
diseas
hematolog
diseas
clinic
data
pulmonari
function
test
pft
laboratori
test
cultur
test
result
medic
record
review
analyz
follow
data
age
gender
smoke
histori
comorbid
treatment
inform
admiss
period
laboratori
test
cultur
test
polymerasechainreact
pcr
assay
previou
pft
pulmonaryrel
treatment
admiss
laboratori
test
cultur
test
pcr
assay
conduct
within
hr
admiss
blood
sputum
urin
cultur
conduct
identif
bacteri
infect
sputum
pcr
assay
conduct
identif
viral
infect
sputum
pcr
assay
perform
use
nasopharyng
aspir
train
doctor
sputum
pcr
assay
detect
influenza
viru
respiratori
syncyti
viru
parainfluenza
viru
coronaviru
rhinoviru
enteroviru
adenoviru
bocaviru
metapneumoviru
defin
mainten
oral
steroid
use
steroid
three
week
shortterm
oral
steroid
use
use
steroid
three
week
less
data
analyz
spss
softwar
spss
window
spss
inc
chicago
il
usa
data
report
mean
standard
deviat
number
percent
group
divid
two
group
respect
eosinophil
count
continu
variabl
compar
use
test
independ
ttest
categor
variabl
compar
use
chisquar
test
fisher
exact
test
variabl
pvalu
univari
analysi
test
logist
regress
analysi
analyz
logist
regress
analysi
white
blood
cell
wbc
crp
convert
binari
variabl
base
optim
cutoff
valu
optim
cutoff
valu
calcul
use
receiv
oper
characterist
cutoff
valu
wbc
crp
mgl
respect
logist
regress
analysi
assess
test
pvalu
consid
statist
signific
multivari
analysi
perform
three
differ
model
analyz
bacteri
pathogen
identif
bacterialvir
pathogen
coidentif
laboratori
find
wbc
crp
analyz
factor
statist
signific
univari
analysi
except
nopathogen
identif
factor
analyz
age
gender
along
factor
respect
exclus
criteria
aecopd
event
elig
event
eosinophil
count
less
event
eosinophil
count
analyz
tabl
show
baselin
characterist
total
event
two
group
statist
signific
differ
two
group
length
hospit
stay
p
experi
intens
unit
care
wbc
p
eosinophil
percent
p
eosinophil
count
p
crp
p
liter
statist
signific
differ
factor
pvalu
variabl
tabl
analyz
past
treatment
associ
pulmonari
condit
admiss
statist
signific
differ
two
group
mainten
oral
steroid
statist
signific
differ
factor
note
pvalu
variabl
tabl
classifi
event
four
group
accord
bacteria
viru
identif
bacteri
pathogen
identif
viral
pathogen
identif
bacterialvir
pathogen
coidentif
nopathogen
identif
bacteri
pathogen
identif
event
bacterialvir
pathogen
coidentif
event
significantli
frequent
group
eosinophil
count
less
respect
nopathogen
identif
event
significantli
frequent
group
eosinophil
count
p
frequenc
viral
pathogen
identif
event
show
statist
signific
differ
two
group
tabl
multivari
model
bacteri
pathogen
identif
event
bacterialvir
coidentif
event
show
statist
signific
differ
two
group
tabl
tabl
show
odd
ratio
confid
interv
pvalu
logist
regress
analysi
studi
first
analyz
whether
bacteri
infect
differenti
base
eosinophil
percent
aecopd
patient
korea
result
show
bacteri
pathogen
identif
event
bacterialvir
pathogen
coidentif
event
significantli
frequent
group
eosinophil
count
less
sinc
studi
use
eosinophil
percent
cutoff
valu
predict
prognosi
treatment
respons
copd
also
use
cutoff
valu
exampl
studi
analyz
prognosi
steroid
inhal
respons
treatment
copd
base
analyz
pneumonia
risk
stabil
stabl
copd
base
eosinophil
make
total
wbc
sever
receptor
cell
surfac
secret
variou
cytokin
research
eosinophil
initi
focus
helminth
infect
allerg
research
progress
found
eosinophil
perform
variou
function
human
bodi
regul
innat
adapt
immun
respons
infect
sinc
anim
studi
show
eosinophil
count
decreas
acut
bacteri
infect
eosinophil
studi
marker
bacteri
reason
decreas
peripher
eosinophil
count
acut
bacteri
infect
accumul
eosinophil
inflammatori
site
inhibit
egress
bone
addit
bacteri
infect
lung
affect
cytokin
chemokin
releas
airway
smooth
muscl
cell
asmc
bacteri
infect
activ
human
asmc
releas
cxc
motif
chemokin
cxcl
increas
neutrophil
hand
bacteri
infect
inhibit
releas
proven
induc
blood
eosinophilia
studi
mani
studi
conduct
relationship
eosinophil
copd
aecopd
copd
analysi
thought
sputum
eosinophilia
could
indirectli
predict
peripher
blood
blood
sputum
eosinophil
count
invers
relat
bacteri
aecopd
analysi
eosinopenia
predict
poor
prognosi
eosinopenia
group
base
eosinophil
count
associ
long
hospit
day
high
result
suggest
eosinopenia
group
show
increas
mortal
rate
durat
hospit
rate
bacteri
infect
higher
eosinophilia
group
studi
relationship
eosinophil
viral
infect
shown
heterogen
result
studi
relationship
viral
infect
eosinophil
children
infant
copd
although
studi
conduct
copd
patient
report
respiratori
viral
infect
show
variou
cytokin
eosinophil
activ
depend
type
furthermor
murin
asthma
model
studi
airway
eosinophil
infiltr
increas
follow
rhinoviru
infect
unlik
control
conclus
eosinophil
expect
show
variou
pattern
depend
viru
type
airway
reactiv
howev
addit
studi
need
lack
studi
copd
patient
biomark
quick
easi
perform
costeffect
despit
medic
econom
level
howev
crp
procalcitonin
difficult
perform
hospit
includ
primari
care
hospit
hand
eosinophil
test
belong
complet
blood
count
test
easili
access
anywher
inexpens
disadvantag
use
eosinophil
biomark
mani
factor
affect
eosinophil
hematolog
disord
cancer
allergi
diseas
medic
studi
patient
diseas
could
affect
eosinophil
initi
exclud
use
inhal
corticosteroid
oral
steroid
analyz
use
univari
multivari
analysi
pulmonaryrel
treatment
admiss
use
rate
oral
agonist
high
korean
copd
patient
prefer
oral
medicin
inhal
also
previou
epidemiolog
studi
use
medic
copd
patient
korea
show
low
use
rate
inhal
differ
use
rate
oral
agonist
two
group
think
affect
result
studi
studi
sever
limit
first
retrospect
design
singl
center
studi
want
analyz
biomark
like
procalcitonin
half
patient
test
procalcitonin
henc
could
evalu
procalcitonin
togeth
second
colon
contamin
could
distinguish
analysi
isol
compens
much
possibl
also
analyz
condit
bronchiectasi
known
highli
colon
differ
two
group
appar
addit
cultur
test
pcr
assay
perform
train
doctor
third
could
analyz
effect
steroid
dose
type
inhal
corticosteroid
group
differ
dose
differ
kind
inhal
use
dose
vari
mg
oral
steroid
use
group
fourth
eosinophil
may
affect
variou
condit
diseas
although
eosinophil
advantag
cheap
easi
use
practic
danger
decid
alon
eosinophil
percent
whether
use
antibiot
aecopd
would
use
use
refer
although
studi
retrospect
singlecent
studi
analyz
variou
factor
largescal
group
multipl
factor
affect
eosinophil
count
analyz
howev
addit
largescal
multicent
random
control
studi
requir
demonstr
result
better
eosinophil
count
may
indic
distinguish
variou
bacteri
infect
aecopd
patient
furthermor
predict
presenc
absenc
bacteri
infect
reliabl
antibiot
treatment
determin
